GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Cash And Cash Equivalents

Eisai Co (TSE:4523) Cash And Cash Equivalents : 円284,791 Mil (As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Eisai Co Cash And Cash Equivalents?

Eisai Co's quarterly cash and cash equivalents increased from Jun. 2023 (円269,305.00 Mil) to Sep. 2023 (円281,452.00 Mil) and increased from Sep. 2023 (円281,452.00 Mil) to Dec. 2023 (円284,791.00 Mil).

Eisai Co's annual cash and cash equivalents increased from Mar. 2021 (円248,740.00 Mil) to Mar. 2022 (円309,633.00 Mil) but then declined from Mar. 2022 (円309,633.00 Mil) to Mar. 2023 (円267,350.00 Mil).


Eisai Co Cash And Cash Equivalents Historical Data

The historical data trend for Eisai Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Cash And Cash Equivalents Chart

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 286,434.00 254,244.00 248,740.00 309,633.00 267,350.00

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 268,002.00 267,350.00 269,305.00 281,452.00 284,791.00

Eisai Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Eisai Co  (TSE:4523) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Eisai Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Eisai Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (TSE:4523) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines